UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study

Rheumatology (Oxford, England), 2023-12, Vol.62 (12), p.3962-3967

2023

Volltextzugriff (PDF)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (1), p.31-40

2019

Volltextzugriff (PDF)

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review

Seminars in arthritis and rheumatism, 2014-04, Vol.43 (5), p.613-626

2014

Volltextzugriff (PDF)

Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis

JAMA surgery, 2017-08, Vol.152 (8), p.e171538

2017

Volltextzugriff (PDF)

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British journal of dermatology (1951), 2019-12, Vol.181 (6), p.1177-1189

2019

Volltextzugriff (PDF)

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.340-347

2016

Volltextzugriff (PDF)

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy

EJD. European journal of dermatology, 2021-06, Vol.31 (3), p.307-317

2021

Volltextzugriff (PDF)

Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities

Journal of drugs in dermatology, 2023-06, Vol.22 (6), p.621-622

2023

Volltextzugriff (PDF)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan

PloS one, 2020-12, Vol.15 (12), p.e0244620

2020

Volltextzugriff (PDF)

Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.594-603

2017

Volltextzugriff (PDF)

Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis

Medicine (Baltimore), 2021-10, Vol.100 (40), p.e27368

2021

Volltextzugriff (PDF)

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting

Rheumatology (Oxford, England), 2015-07, Vol.54 (7), p.1170-1176

2015

Volltextzugriff (PDF)

Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis

Expert opinion on drug safety, 2021-03, Vol.20 (3), p.275-292

2021

Volltextzugriff (PDF)

Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment

Clinics in dermatology, 2020-11, Vol.38 (6), p.613-628

2020

Volltextzugriff (PDF)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.329-337

2019

Volltextzugriff (PDF)

A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry

Rheumatology (Oxford, England), 2020-10, Vol.59 (10), p.2796-2805

2020

Volltextzugriff (PDF)

Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization

Allergy (Copenhagen), 2015-07, Vol.70 (7), p.784-794

2015

Volltextzugriff (PDF)

Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases

Deutsches Ärzteblatt international, 2022-02, Vol.119 (6), p.88-95

2022

Volltextzugriff (PDF)

The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection

Journal of pediatric gastroenterology and nutrition, 2019-03, Vol.68 (3), p.334-338

2019

Volltextzugriff (PDF)

Adverse reactions to biologic agents and their medical management

Nature reviews. Rheumatology, 2014-10, Vol.10 (10), p.612-627

2014

Volltextzugriff (PDF)

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

American journal of clinical dermatology, 2024-07, Vol.25 (4), p.595-607

2024

Volltextzugriff (PDF)

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.420-428.e1

2015

Volltextzugriff (PDF)

COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology

Nature reviews. Gastroenterology & hepatology, 2021-10, Vol.18 (10), p.705-715

Neurath, Markus F

2021

Volltextzugriff (PDF)

Safety Summary of Pediatric Inflammatory Bowel Disease Therapies

Gastroenterology clinics of North America, 2023-09, Vol.52 (3), p.535-548

2023

Volltextzugriff (PDF)

Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses

United European Gastroenterology Journal, 2019-12, Vol.7 (10), p.1285-1303

2019

Volltextzugriff (PDF)

1 – 25 von 54.818

Suche als RSS-Feed

Aktive Filter

ThemaRisk Factors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51.472)
Mit Volltextzugriff
(42.855)

Publikationsform

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(50.113)
Science & Technology
(49.984)
Life Sciences & Biomedicine
(49.426)
Humans
(46.939)
Medical Sciences
(46.541)
Male
(34.948)
Female
(33.817)
Time Factors
(30.270)
Adult
(23.964)
Middle Aged
(23.932)
Aged
(16.944)
Pharmacology. Drug Treatments
(14.069)
Animals
(10.433)
Treatment Outcome
(9.530)
Adolescent
(8.190)
Surgery
(7.122)
Age Factors
(6.790)
Fundamental And Applied Biological Sciences. Psychology
(6.301)
Follow-Up Studies
(5.996)
Surgery . Transplantations, Organ And Tissue Grafts. Graft Diseases
(5.990)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(54.726)
Journals@Ovid Complete
(32.161)
IngentaConnect Journals
(28.445)
EZB Free E-Journals
(21.199)
NUS Single-Journal Subscriptions
(15.347)
Elsevier ScienceDirect Journals Complete
(14.480)
IngentaConnect Journals
(10.704)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(9.399)
Wiley Online Library Journals Frontfile Complete
(8.977)
Wiley Online Library Full Collection 2018
(7.592)
Springer Nature - Complete Springer Journals
(4.851)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(3.766)
Oxford University Press Journals Current
(3.452)
Oxford Journals 2020 Medicine
(2.669)
Taylor & Francis Journals
(1.871)
Taylor & Francis:Master (3349 titles)
(1.866)
Taylor & Francis Current Content Access
(1.805)
JSTOR
(1.676)
Nature Journals
(1.635)
BMJ Journals
(1.467)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(19)

Menü

Weitere Dienste

Einstellungen

The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review

Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy

Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan

Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting

Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis

Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry

Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization

Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases

The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection

Adverse reactions to biologic agents and their medical management

The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis

COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology

Safety Summary of Pediatric Inflammatory Bowel Disease Therapies

Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses

Aktive Filter

Suchergebnisse filtern